183 related articles for article (PubMed ID: 23418396)
41. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
42. Research Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.
Günther T; Culler M; Schulz S
Mol Endocrinol; 2016 Apr; 30(4):479-90. PubMed ID: 26967369
[TBL] [Abstract][Full Text] [Related]
43. Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients.
Waser B; Cescato R; Liu Q; Kao YJ; Körner M; Christ E; Schonbrunn A; Reubi JC
Am J Pathol; 2012 May; 180(5):1942-9. PubMed ID: 22538189
[TBL] [Abstract][Full Text] [Related]
44. Filamin A is required for somatostatin receptor type 5 expression and pasireotide-mediated signaling in pituitary corticotroph tumor cells.
Treppiedi D; Di Muro G; Mangili F; Catalano R; Giardino E; Barbieri AM; Locatelli M; Arosio M; Spada A; Peverelli E; Mantovani G
Mol Cell Endocrinol; 2021 Mar; 524():111159. PubMed ID: 33428965
[TBL] [Abstract][Full Text] [Related]
45. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
46. Influence of the somatostatin receptor sst2 on growth factor signal cascades in human glioma cells.
Held-Feindt J; Forstreuter F; Pufe T; Mentlein R
Brain Res Mol Brain Res; 2001 Feb; 87(1):12-21. PubMed ID: 11223155
[TBL] [Abstract][Full Text] [Related]
47. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide.
Park C; Yang I; Woo J; Kim S; Kim J; Kim Y; Sohn S; Kim E; Lee M; Park H; Jung J; Park S
Endocr J; 2004 Apr; 51(2):227-36. PubMed ID: 15118275
[TBL] [Abstract][Full Text] [Related]
48. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPgammaS binding.
Siehler S; Hoyer D
Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):500-9. PubMed ID: 10598789
[TBL] [Abstract][Full Text] [Related]
49. Somatostatin analogs regulate tumor corticotrophs growth by reducing ERK1/2 activity.
Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Sala E; Locatelli M; Arosio M; Spada A; Mantovani G; Peverelli E
Mol Cell Endocrinol; 2019 Mar; 483():31-38. PubMed ID: 30611770
[TBL] [Abstract][Full Text] [Related]
50. A novel pathway activated by somatostatin receptor type 2 (SST2): Inhibition of pituitary tumor cell migration and invasion through cytoskeleton protein recruitment.
Peverelli E; Giardino E; Treppiedi D; Catalano R; Mangili F; Locatelli M; Lania AG; Arosio M; Spada A; Mantovani G
Int J Cancer; 2018 May; 142(9):1842-1852. PubMed ID: 29226331
[TBL] [Abstract][Full Text] [Related]
51. Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies.
Doll C; Konietzko J; Pöll F; Koch T; Höllt V; Schulz S
Br J Pharmacol; 2011 Sep; 164(2):298-307. PubMed ID: 21449911
[TBL] [Abstract][Full Text] [Related]
52. Fates of endocytosed somatostatin sst2 receptors and associated agonists.
Koenig JA; Kaur R; Dodgeon I; Edwardson JM; Humphrey PP
Biochem J; 1998 Dec; 336 ( Pt 2)(Pt 2):291-8. PubMed ID: 9820803
[TBL] [Abstract][Full Text] [Related]
53. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
54. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
55. Homologous and heterologous regulation of somatostatin receptor 2.
Elberg G; Hipkin RW; Schonbrunn A
Mol Endocrinol; 2002 Nov; 16(11):2502-14. PubMed ID: 12403839
[TBL] [Abstract][Full Text] [Related]
56. G protein-coupled receptor kinase-mediated phosphorylation regulates post-endocytic trafficking of the D2 dopamine receptor.
Namkung Y; Dipace C; Javitch JA; Sibley DR
J Biol Chem; 2009 May; 284(22):15038-51. PubMed ID: 19332542
[TBL] [Abstract][Full Text] [Related]
57. Internalization of somatostatin receptors in brain and periphery.
Csaba Z; Dournaud P
Prog Mol Biol Transl Sci; 2023; 196():43-57. PubMed ID: 36813365
[TBL] [Abstract][Full Text] [Related]
58. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
[TBL] [Abstract][Full Text] [Related]
59. Nonpeptidyl somatostatin agonists demonstrate that sst2 and sst5 inhibit stimulated growth hormone secretion from rat anterior pituitary cells.
Parmar RM; Chan WW; Dashkevicz M; Hayes EC; Rohrer SP; Smith RG; Schaeffer JM; Blake AD
Biochem Biophys Res Commun; 1999 Sep; 263(2):276-80. PubMed ID: 10491284
[TBL] [Abstract][Full Text] [Related]
60. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis.
Stroh T; Jackson AC; Sarret P; Dal Farra C; Vincent JP; Kreienkamp HJ; Mazella J; Beaudet A
Endocrinology; 2000 Jan; 141(1):354-65. PubMed ID: 10614658
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
